New perspectives in the management of dyslipidemia and the role of PCSK9 inhibitors
Semergen. 2026 Jul 7;52(6):102799. doi: 10.1016/j.semerg.2026.102799. Online ahead of print.ABSTRACTCardiovascular diseases continue to be the leading cause of morbidity and mortality worldwide. Reducing LDL cholesterol (LDL-c) is one of the fundamental pillars of cardiovascular prevention; however,

